



## **CRISPR Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting**

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

**Title:** Development of an *In Vivo* Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucoma

**Session Type:** In-Person Oral Presentation

**Session Title:** Ophthalmic and Auditory: Delivery Innovations

**Abstract Number:** 87

**Location:** Room 318 – 323

**Session Date and Time:** Wednesday, May 8, 2024, 1:30 p.m. – 3:15 p.m. ET

Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at <https://annualmeeting.asgct.org/>. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at [www.crisprtx.com](http://www.crisprtx.com) once the presentation concludes.

### **About CRISPR Therapeutics**

Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit [www.crisprtx.com](http://www.crisprtx.com).

### **Investor Contact:**

Susan Kim

+1-617-307-7503

[susan.kim@crisprtx.com](mailto:susan.kim@crisprtx.com)

### **Media Contact:**

Rachel Eides

+1-617-315-4493

[rachel.eides@crisprtx.com](mailto:rachel.eides@crisprtx.com)



Source: CRISPR Therapeutics AG